ReCode Therapeutics is a company focused on developing RNA-targeted therapeutics for pulmonary diseases, including fibrosis.

ReCode Therapeutics

Structure is a biotechnology company specializing in the development of novel therapies for fibrotic diseases and related conditions.

Structure

Visterra Inc is a biotechnology company that focuses on developing antibody-based therapies for infectious diseases and other conditions.

Visterra Inc

GlycoMimetics Inc is a biotechnology company that specializes in the development of small molecule drugs for the treatment of various diseases, including cancer and hematologic conditions.

GlycoMimetics Inc

Atox Bio is a biotechnology company that focuses on the development of novel immunotherapies for the treatment of severe infections and related complications.

Atox Bio

Morphic Therapeutic is a biotechnology company specializing in the development of oral integrin therapies for the treatment of chronic diseases, including fibrosis.

Morphic Therapeutic

Pliant Therapeutics is a biotechnology company focused on the development of novel therapies for fibrotic diseases, including idiopathic pulmonary fibrosis and liver fibrosis.

Pliant Therapeutics

Avalo Therapeutics is a biotechnology company that specializes in the development of targeted therapies for fibrotic diseases and related conditions.

Avalo Therapeutics

SAGE Therapeutics is a biopharmaceutical company that focuses on the development of therapies for central nervous system disorders, including depression and neurological conditions.

SAGE Therapeutics

Dicerna Pharmaceuticals is a biopharmaceutical company specializing in the development of RNA interference (RNAi) therapies for the treatment of rare diseases and liver-related conditions.

Dicerna Pharmaceuticals

Galecto, Inc. is a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer. The company's pipeline includes GB0139, an inhaled inhibitor of galectin-3 for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrosis conditions, as well as GB1211, a modulator of galectin-3 and LOXL2 for the treatment of myelofibrosis and other fibrotic diseases.

HBM Healthcare Investments AG is a Switzerland-based venture capital company investing in emerging companies, mainly from the biotechnology and human medicine, diagnostics, as well as medical technology sectors. The Company focuses on unlisted companies, with two-thirds of assets being invested in private companies that offer high value-creation potential. As a holding company, it is involved in the acquisition, disposal and management of a diversified portfolio, as well as in financing and supporting the portfolio firms as a key partner. It focuses on companies with products either at an advanced stage of development or already available on the market. The primary investment areas are Western Europe and the United States. The Company's portfolio includes approximately 25 companies. As of March 31, 2012, the Company had six wholly owned subsidiaries, including three subsidiaries on Cayman Islands, two Barbados-based subsidiaries and a subsidiary in the United States.

Zosano Pharma

Seer

BioAtla

Mineralys Therapeutics

Nabriva Therapeutics

Acrivon Therapeutics

Ambrx

Aptinyx

Arcutis Biotherapeutics

IVERIC bio

PTC Therapeutics

C4 Therapeutics

Pyxis Oncology

ChemoCentryx

Galera Therapeutics

Harmony Biosciences

Homology Medicines

Infinity Pharmaceuticals

Instil Bio

IO Biotech

HBM Healthcare Investments AG

HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.

SIX:HBMN

Galecto, Inc.

Last Close

182.20

30/08 15:31

Market Cap

11.45M

Beta: 0.77

Volume Today

810

Avg: 3.52K

PE Ratio

−6.76

PFCF: −861.64

Dividend Yield

4.23%

Payout:0%